Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers
Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers
复制标题
DOI：
10.1007/s10147-008-0770-6
复制
发表时间：
2008-10-01
影响因子：
3.3
通讯作者：
Nishiguchi, Yukio
中科院分区：
文献类型：
--
作者：
Ogawa, Yoshinari;Hai, Eishu;Nishiguchi, Yukio
背景。乳腺癌是一种激素依赖性肿瘤。大多数乳腺癌细胞都有雄激素受体（AR），但AR表达的临床价值尚不清楚。应用免疫组化技术对227例原发性乳腺癌的AR表达进行了评估。分析AR表达与临床病理因素及生物标志物的关系。半定量评估AR表达，染色细胞比例超过10%的肿瘤视为阳性。ar阳性率在较小肿瘤（P = 0.045）、淋巴结转移阴性肿瘤（P = 0.045）、scirrhouse型肿瘤（P < 0.0001）、低组织学分级肿瘤（P = 0.0001）和p53阴性肿瘤（P = 0.0097）中较高。虽然AR与绝经状态无关，但79%的AR高表达（bbb50 %染色细胞）发生在绝经后妇女。AR与雌激素受体（ER, P = 0.027）和孕激素受体（PR, P = 0.016）表达相关，但与人表皮生长因子受体2 （Her2）表达无关。对于这些受体的共表达，42例三阴性（ER/ PR/ her2阴性）肿瘤中有18例（43%）为ar阳性。乳腺癌中AR表达与低恶性相关。对AR表达的评估可能会为乳腺癌提供新的治疗策略，特别是绝经后妇女和激素受体三阴性肿瘤妇女。
Background. Breast cancer is a hormone-dependent tumor. Most breast cancer cells have an androgen receptor (AR), but the clinical value of AR expression is unclear.Methods. AR expression was evaluated in 227 primary breast cancers using immunohistochemistry. The relation of AR expression to clinicopathological factors and biomarkers was analyzed. AR expression was assessed semiquantitatively, and tumors with more than 10% of stained cells were regarded as positive.Results. The AR-positive rate was higher in smaller tumors (P = 0.045), tumors with negative lymph node metastasis (P = 0.045), scirrhous-type tumors (P < 0.0001), tumors of low histological grade (P = 0.0001), and p53-negative tumors (P = 0.0097). Although AR had no relation to menopausal status, 79% of cases of high AR expression (> 50% stained cells) were in postmenopausal women. AR was related to estrogen receptor (ER; P = 0.027) and progesterone receptor (PR; P = 0.016) expression, but showed no relation to human epidermal growth factor receptor type 2 (Her2) expression. Regarding the coexpression of these receptors, 18 of the 42 cases of triple-negative (ER/ PR/ Her2-negative) tumors (43%) were AR-positive.Conclusion. AR expression is related to low malignancy in breast cancer. The assessment of AR expression may lead to new treatment strategies for breast cancer, especially in postmenopausal women and in women with tumors that show triple negativity for hormone receptors.